PL2368913T3 - Przeciwciała ze zmodyfikowaną glikozylacją - Google Patents

Przeciwciała ze zmodyfikowaną glikozylacją

Info

Publication number
PL2368913T3
PL2368913T3 PL11163178T PL11163178T PL2368913T3 PL 2368913 T3 PL2368913 T3 PL 2368913T3 PL 11163178 T PL11163178 T PL 11163178T PL 11163178 T PL11163178 T PL 11163178T PL 2368913 T3 PL2368913 T3 PL 2368913T3
Authority
PL
Poland
Prior art keywords
glyco
engineered antibodies
engineered
antibodies
Prior art date
Application number
PL11163178T
Other languages
English (en)
Inventor
Manfred Schuster
Ralf Kircheis
Andreas Nechansky
Wolfgang Jost
Gilbert Gorr
Original Assignee
Greenovation Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37635723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2368913(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Greenovation Biotech Gmbh filed Critical Greenovation Biotech Gmbh
Publication of PL2368913T3 publication Critical patent/PL2368913T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL11163178T 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją PL2368913T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06450095A EP1878747A1 (en) 2006-07-11 2006-07-11 Glyco-engineered antibodies
EP07801422.2A EP2044121B1 (en) 2006-07-11 2007-07-11 Glyco-engineered antibodies
EP11163178.4A EP2368913B1 (en) 2006-07-11 2007-07-11 Glyco-engineered antibodies

Publications (1)

Publication Number Publication Date
PL2368913T3 true PL2368913T3 (pl) 2015-05-29

Family

ID=37635723

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07801422T PL2044121T3 (pl) 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją
PL11163178T PL2368913T3 (pl) 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07801422T PL2044121T3 (pl) 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją

Country Status (12)

Country Link
US (2) US9051577B2 (pl)
EP (3) EP1878747A1 (pl)
JP (1) JP5424878B2 (pl)
KR (1) KR101565949B1 (pl)
CN (1) CN101495514A (pl)
CA (1) CA2657605C (pl)
DK (2) DK2044121T3 (pl)
ES (2) ES2529769T3 (pl)
IL (1) IL196022A (pl)
PL (2) PL2044121T3 (pl)
PT (1) PT2368913E (pl)
WO (1) WO2008006554A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637252A1 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Plants and plant cells having inhibited expression of .alpha.1,3-fucosyltransferase and .beta.1,2-xylosyltransferase
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8637435B2 (en) 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
JP5731827B2 (ja) 2008-03-03 2015-06-10 グライコフィ， インコーポレイテッド 下等真核生物中での組換えタンパク質の表面ディスプレイ
CA2723197C (en) * 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EP2379598B1 (en) 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
EA024695B1 (ru) 2009-03-16 2016-10-31 Сефалон Острэйлиа Пти Лтд. Гуманизированные антитела с противоопухолевой активностью
KR20120087882A (ko) 2009-07-30 2012-08-07 에프. 호프만-라 로슈 아게 효소적 항체 가공
AU2010314798B2 (en) 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
KR101930961B1 (ko) 2010-02-24 2018-12-19 머크 샤프 앤드 돔 코포레이션 피키아 파스토리스에서 생산된 치료 당단백질 상의 ｎ-글리코실화 부위 점유를 증가시키는 방법
JP6121904B2 (ja) * 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
US9187564B2 (en) 2010-10-05 2015-11-17 Hoffmann-La Roche Inc. Antibodies against human TWEAK and uses thereof
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
FR2980271B1 (fr) * 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
US9365881B2 (en) 2011-10-05 2016-06-14 Hoffmann-La Roche Inc. Process for antibody G1 glycoform production
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
EP2812027A1 (en) 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
EP2956482B1 (en) 2013-02-14 2017-06-28 Innate Pharma Treatment of peripheral t cell lymphoma
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
JP6936150B2 (ja) 2015-03-17 2021-09-15 エレヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングｅｌｅｖａ ＧｍｂＨ グリコシル化リソソームタンパク質、その製造方法および使用
CA3001676C (en) 2015-10-12 2022-12-06 Aprogen Kic Inc. Anti-cd43 antibody and use thereof for cancer treatment
KR20180118673A (ko) 2016-03-15 2018-10-31 이나뜨 파르마 항-mica 항체
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
KR20230173745A (ko) 2016-10-21 2023-12-27 이나뜨 파르마 에스.에이. 항-kir3dl2 작용제에 의한 치료
KR102348638B1 (ko) * 2019-11-21 2022-01-11 (주)지플러스 생명과학 비푸코실화된 담배를 이용하여 생산한 항체 및 이의 용도
WO2021101351A2 (ko) * 2019-11-21 2021-05-27 (주)지플러스 생명과학 비푸코실화된 담배를 이용하여 생산한 항체 및 이의 용도
US20210322539A1 (en) * 2020-04-17 2021-10-21 Yigal Adir Cure to new viruses and other diseases that do not have current cure
CN118489061A (zh) * 2021-12-28 2024-08-13 积水医疗株式会社 检测方法和检测试剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA1332367C (en) * 1988-09-28 1994-10-11 Richard Mark Bartholomew Method for the reduction of heterogeneity of monoclonal antibodies
ES2145004T3 (es) 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DK1228231T3 (da) * 1999-10-26 2007-10-29 Plant Res Int Bv Mammal-type glycosylering i planter
DE10003573A1 (de) * 2000-01-27 2001-08-09 Mpb Cologne Gmbh Molecular Pla Hemmung von Kohlenhydrat-modifizierenden Enzymen in Wirtsorganismen
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
AR042145A1 (es) * 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2549932C (en) * 2002-12-20 2013-08-20 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2005000225A2 (en) * 2003-06-02 2005-01-06 University Of Oxford Production of rabies antibodies in plants
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
PE20051053A1 (es) * 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
WO2005113003A2 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
CA2573505C (en) 2004-07-14 2013-06-25 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
SI1771482T1 (sl) 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
GT200600020A (es) 2005-01-13 2006-11-08 Procedimiento de tratamiento
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern

Also Published As

Publication number Publication date
ES2428875T3 (es) 2013-11-12
US20150284461A1 (en) 2015-10-08
IL196022A (en) 2015-01-29
JP2009542750A (ja) 2009-12-03
DK2044121T3 (da) 2013-10-07
KR20090039756A (ko) 2009-04-22
DK2368913T3 (en) 2015-02-16
WO2008006554A8 (en) 2008-03-13
WO2008006554A2 (en) 2008-01-17
CA2657605C (en) 2018-11-06
EP2368913B1 (en) 2014-12-24
IL196022A0 (en) 2011-08-01
EP2044121B1 (en) 2013-08-21
EP2044121A2 (en) 2009-04-08
CA2657605A1 (en) 2008-01-17
CN101495514A (zh) 2009-07-29
US9051577B2 (en) 2015-06-09
JP5424878B2 (ja) 2014-02-26
US20090291078A1 (en) 2009-11-26
US10253098B2 (en) 2019-04-09
EP2368913A3 (en) 2011-11-23
WO2008006554A3 (en) 2008-04-24
ES2529769T3 (es) 2015-02-25
EP2368913A2 (en) 2011-09-28
PT2368913E (pt) 2015-03-17
KR101565949B1 (ko) 2015-11-06
PL2044121T3 (pl) 2014-01-31
EP1878747A1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
IL196022A0 (en) Glyco-engineered antibodies
GB0708002D0 (en) Antibodies
DE602007002700D1 (en) Interventionsfreies frac-system
EP2078282A4 (en) ELECTRONIC COUPONS
EP2033216A4 (en) ELEKTROADHÄSION
DE602007008085D1 (en) Dihydropyrazolopyrimidinonderivate
DE602007014031D1 (en) Luftreifensatz
GB0615662D0 (en) Antibody
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
DE602007003855D1 (en) Isothermer reaktor
EP1983992A4 (en) 2-IMINO-BENZIMIDAZOLES
DE602007001601D1 (en) Glasuntersuchung
HK1109502A1 (en) Battary can
GB0718737D0 (en) Antibodies
DE602007006989D1 (en) Spiropiperidinderivate
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
EP2084019A4 (en) PAINT SCRAPER
EP2015785A4 (en) ANTIGEN AGRM2
EP2024567A4 (en) TONTAPETE
EP2007388A4 (en) OPIOPATHIEN
GB0713585D0 (en) Equivalent
DK1989111T3 (en) Satellitluftbremseapparat
EP1974618A4 (en) UNDERWEAR